SUBSCRIBERS
Trendlines Group still a 'buy': DBS research
Published Thu, Mar 17, 2016 · 09:50 PM
Singapore
DBS Group Research has maintained its buy rating on The Trendlines Group, despite the Catalist-listed medical (medtech) and agricultural tech (agtech) incubator losing the bid to renew its agtech incubator licence.
It is "not a material loss", DBS analyst Sachin Mittal said in a note on Thursday. "Given that medtech companies comprise an estimated 70-8…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Meta releases early versions of its Llama 3 AI model
Seatrium unit ordered to pay US$108 million in arbitration over equipment supply contracts
TSMC estimates losses of US$92.4 million due to Taiwan earthquake
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
US: Wall St opens higher as some chip stocks bounce back after selloff
Blackstone reports 1% rise in Q1 earnings